Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating GS-5829 (alobresib) as a single agent and with enzalutamide in metastatic castration-resistant prostate cancer; study terminated with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• GS-5829 (GS-5829)

Snippet

Sponsor: Gilead Sciences | Conditions: Metastatic Castrate-Resistant Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-12-08